introduction
Renal bone disease is a general term for the spectrum of complex changes to mineral metabolism and bone strength seen in patients with chronic kidney disease. 1 It is characterised by altered calcium, phosphate and vitamin D homeostasis and an altered physiological response to parathyroid hormone. The consequences of these changes include diminished bone strength and mineralisation (renal osteodystrophy) [2] [3] [4] as well as soft tissue and vascular calcification which occasionally results in the clinical syndrome of calcific uraemic arteriolopathy. 5 These systemic complications are collectively referred to as chronic kidney disease mineral and bone disorder. 1 This disorder impacts on cardiovascular disease progression, morbidity and mortality. 6, 7 Renal osteodystrophy encompasses a number of histologically different conditions. These include both low (adynamic bone disease) and high (osteitis fibrosa) bone turnover states, as well as conditions of altered mineralisation. These conditions all decrease bone strength and predispose the patient to pathological fractures. 2, 6 Calcium and phosphate physiology Plasma concentrations of calcium and phosphate are normally tightly regulated. Calcium absorption from the gut is stimulated by calcitriol whereas phosphate absorption largely varies with dietary intake and has less regulation by calcitriol.
Most of the absorbed calcium and phosphate is stored in the bones with very small amounts present in the circulation. Both calcium and phosphate are filtered at the glomerulus. Calcium reabsorption is regulated by a calcium sensing receptor and increased by parathyroid hormone. Phosphate reabsorption is decreased by parathyroid hormone and fibroblast growth factor-23 and increased by calcitriol (see Fig. 1 
online).

Calcitriol and vitamin D
Vitamin D (calciferol) is synthesised in vivo by photoactivation of steroid precursors in the skin. Calciferol is hydroxylated in the liver to calcidiol (25-hydroxycalciferol) which is subsequently bioactivated to calcitriol (1,25-dihydroxycalciferol) by 1-a-hydroxylase. Most circulating calcitriol is produced by 1-a-hydroxylation in the proximal tubule. It is now known that hydroxylation can also occur in many extra-renal tissues, where calcitriol is presumed to have a paracrine effect. 8 Calcitriol is the most potent vitamin D analogue, but calcidiol may have a significant role in immunomodulation, cancer reduction, insulin secretion and other effects. 9-11 Vitamin D analogues increase the body stores of calcium.
Parathyroid hormone
Parathyroid hormone maintains the concentration of ionised calcium. It is synthesised and released into the circulation in response to hypocalcaemia and hyperphosphataemia. 
patient education to limit the progression of renal bone disease
The management of chronic renal failure is multidisciplinary.
In particular, dietary education regarding a low phosphate diet may limit progression of chronic kidney disease mineral and bone disorder. education regarding medication adherence, dialysis attendance and regular medical review is also important. early referral to a specialist is recommended.
Treatment
Preventing renal bone disease is a priority because advanced disease responds poorly to treatment. observational studies show that many patients do not achieve their desired treatment targets, although over the last decade some improvement has been observed. 7, 14 There is an opportunity for both clinicians and patients to improve management to optimise clinical outcomes (see Fig. 3 online).
Phosphate reduction
Controlling phosphate concentrations helps to control the secretion of parathyroid hormone. 
Dietary restriction
Renal replacement therapy
Dialysis removes phosphate and this is enhanced if the duration and frequency of dialysis are increased.
Vitamin D analogues
Multiple 
Calcium salts
